^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PDL1≥1%...First-line therapy…Nivolumab/ipilimumab/paclitaxel/carboplatin (squamous)
    Secondary therapy:
    carboplatin + paclitaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    PD-L1 expression positive (≥1%-49%)…squamous cell carcinoma…Useful in certain circumstances...Nivolumab + ipilimumab
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Int J Clin Oncol
    Title:

    First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

    Published date:
    02/19/2022
    Excerpt:
    6-month and 1-year OS rates were 100% (95% CI 100.0–100.0) and 93% (95% CI 74.3–98.2) with nivolumab plus ipilimumab combined with chemotherapy versus 83% (95% CI 64.5–92.7) and 60% (95% CI 40.5–75.0) with chemotherapy, respectively. OS by histology (squamous and nonsquamous) and tumor PD-L1 expression (< 1% and ≥ 1%) also favored nivolumab plus ipilimumab combined with chemotherapy compared with chemotherapy (Online Resource 1).
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1007/s10147-022-02120-0
    Trial ID:
    CheckMate 9LA
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Opdivo® (Nivolumab) Intravenous Infusion Approved for First–Line Treatment of Advanced or Recurrent Non-Small Cell Lung Cancer in Combination Therapy in Taiwan

    Excerpt:
    Ono Pharmaceutical Co., Ltd...announced that Ono Pharma Taiwan Co., Ltd. (“OPTW”), a Taiwanese subsidiary of ONO, received the approval of Opdivo® (nivolumab)...from the Taiwan Food and Drug Administration (TFDA) in Taiwan for additional indication of the first-line treatment of advanced or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations, in the following combination therapies:...Combination therapy with Opdivo and Yervoy* (tumors express PD-L1 ≧1%)...